Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 4Phase 1/2 2

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

NIH 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Lymphoid 1CNS 1

Conditions

Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Brain Neoplasms 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 222Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × omipalisib × Clear all
NCT02015117 2026-04-13

Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases

National Cancer Institute (NCI)

Phase 1 Active not recruiting
10 enrolled
CNS

Brain Neoplasms

NCT02070549 2025-02-13

Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
46 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00972686 2017-05-09

FTIH

GlaxoSmithKline

Phase 1 Completed
79 enrolled
Lymphoid

Lymphoma

NCT01248858 2017-05-09

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.

GlaxoSmithKline

Phase 1 Terminated
69 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡